Business
Novo Nordisk and Eli Lilly have been battling head-to-head in an exploding obesity market. They should never have been compared apples to apples.
FEATURED STORIES
Analysts parsed the limited data available for Pfizer’s obesity candidate on the pharma’s fourth-quarter earnings call Tuesday, looking for any nugget of additional context.
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
After suffering in the wake of expired tax incentives for pharmas, the island is trying to take advantage of geopolitics to grow its drug manufacturing sector.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Pharma, biotech and life sciences organizations strengthen their leadership teams and boards.
The two companies will pair up to advance Turnstone’s lead program, RIVAL-01, in multiple cancer studies and will also work together to identify additional novel product candidates based on Turnstone’s vaccinia virus platform for future independent development.
As Biogen stays in the hunt for an Alzheimer’s treatment with the recent presentation of data about aducanumab made at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) conference on December 5, it’s expanding its pipeline.
Arcus Biosciences and Genentech, a Roche company, are partnering on two clinical trials for colorectal and pancreatic cancer. They will evaluate Arcus’s AB928 in various combinations.
Seminal report focuses on hope, hype, promise, and peril of AI use in medical arena
Brain-disease focused Cerevance and Takeda Pharmaceutical forged a research collaboration to tackle gastrointestinal disorders that have their roots in the central nervous system.
Douglas Brenneman, who spent much of his career at the National Institute of Child Health and Human Development at the National Institutes of Health and as a senior research fellow at Johnson & Johnson, spoke with BioSpace about CBD and his scientific advisory work.
FerGene launched last month with a $570 million investment from Ferring and Blackstone Life Sciences.
Summit Therapeutics plc reports its financial results and provides an update on its operational progress for the third quarter and nine months ended 31 October 2019.
Recipharm, the contract development and manufacturing organisation has partnered with biotechnology company Aptahem, for the formulation of Apta-1 drug candidate.